10x Genomics, Inc. (TXG): Results of Operations and Financial Condition
10x Genomics, Inc. (TXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 10x Genomics Reports Second Quarter 2026 Financial Results PLEASANTON, Calif. August 6, 2026 – 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the se
How this was made
The 30-second read
Why it matters
The key tradable datapoint is the raised full-year revenue range, supported by higher gross margin and commentary on early order flow for Atera. Offsetting factors include higher operating expenses and a net loss vs the prior-year quarter, with several line items attributed to non-recurring patent settlement effects.
Market read
A guidance raise with specific revenue range and supporting margin/cash details makes this a direct catalyst for TXG positioning into and after the earnings call.
What to watch
Tariff refunds and lower inventory write-downs boosted gross margin; traders may watch whether those benefits are repeatable in subsequent quarters, and whether operating expenses re-accelerate once settlement gains/losses normalize.
10x Genomics reported second-quarter revenue of $151.0 million, raised full-year 2026 revenue guidance to $610 million to $630 million, and cited strong early order flow for Atera.
Revenue excluding non-recurring patent litigation settlement revenue increased 3% over the corresponding period of 2025 and full-year revenue guidance was raised, but reported revenue declined to $151.0 million from $172.9 million and the company recorded operating and net losses versus prior-year income.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $151.0 million | – | – |
| Revenue excluding non-recurring revenue related to patent litigation settlementsother | $149.4 million | – | increased 3% |
| Products and services revenueGAAP | $149,094 (in thousands) | – | – |
| License and royalty revenueGAAP | $1,942 (in thousands) | – | – |
| Cost of products and services revenueGAAP | $38,539 (in thousands) | – | – |
| Gross profitGAAP | $112,497 (in thousands) | – | – |
| Gross marginGAAP | 74% | – | – |
| Research and developmentGAAP | $56,791 (in thousands) | – | – |
| Selling, general and administrativeGAAP | $78,661 (in thousands) | – | – |
| Gain on settlementGAAP | $(3,400) (in thousands) | – | – |
| Total operating expensesGAAP | $132.1 million | – | 39% increase |
| Operating lossGAAP | $19.6 million | – | – |
| Interest incomeGAAP | $4,797 (in thousands) | – | – |
| Interest expenseGAAP | — | – | – |
| Other income (expense), netGAAP | $(3,887) (in thousands) | – | – |
| Total other incomeGAAP | $910 (in thousands) | – | – |
| Income (loss) before provision for income taxesGAAP | $(18,645) (in thousands) | – | – |
| Provision for (benefit from) income taxesGAAP | $(714) (in thousands) | – | – |
| Net lossGAAP | $17.9 million | – | – |
| Net loss per share, basicGAAP | $(0.14) | – | – |
| Net loss per share, dilutedGAAP | $(0.14) | – | – |
| Total stock-based compensation expenseGAAP | $25,616 (in thousands) | – | – |
| Six months ended June 30, 2026 revenueGAAP | $301,879 (in thousands) | – | – |
| Six months ended June 30, 2026 gross profitGAAP | $218,675 (in thousands) | – | – |
| Six months ended June 30, 2026 total operating expensesGAAP | $255,276 (in thousands) | – | – |
| Six months ended June 30, 2026 net lossGAAP | $(31,401) (in thousands) | – | – |
| Six months ended June 30, 2026 net loss per diluted shareGAAP | $(0.24) | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Single Cell instrumentsNot disclosed. | $3,087 (in thousands) | – | – |
| Spatial instrumentsSpatial includes the Company’s Visium and Xenium products. | $4,574 (in thousands) | – | – |
| Total instruments revenueNot disclosed. | $7,661 (in thousands) | – | – |
| Single Cell consumablesNot disclosed. | $88,451 (in thousands) | – | – |
| Spatial consumablesSpatial includes the Company’s Visium and Xenium products. | $42,301 (in thousands) | – | – |
| Total consumables revenueNot disclosed. | $130,752 (in thousands) | – | – |
| ServicesNot disclosed. | $10,681 (in thousands) | – | – |
| License and royalty revenuePatent litigation settlement-related revenue was non-recurring. | $1,942 (in thousands) | – | – |
| United StatesIncludes license and royalty revenue. | $82,109 (in thousands) | – | – |
| Americas excluding United StatesNot disclosed. | $2,917 (in thousands) | – | – |
| Europe, Middle East and AfricaNot disclosed. | $39,972 (in thousands) | – | – |
| ChinaNot disclosed. | $14,968 (in thousands) | – | – |
| Asia-Pacific excluding ChinaNot disclosed. | $11,070 (in thousands) | – | – |
full year 2026 outlook
- Revenue$610 million to $630 million
- NoteExcluding the non-recurring license and royalty revenue related to patent litigation settlements in both 2026 and 2025, this represents 2% to 5% growth over full year 2025.
What drove it
- Revenue excluding non-recurring settlement revenue in both periods increased 3% over the corresponding period of 2025.
- Gross margin increased primarily due to lower manufacturing costs, including $2.6 million of tariff refunds, and lower inventory write-downs.
- The gross-margin improvement was partially offset by a decrease in non-recurring license and royalty revenue.
- The company cited extraordinary customer response to Atera, strong early order flow, and continued momentum across the rest of the business.
- 10x Genomics acquired Proteintech Genomics, a division within Proteintech Group, to add protein detection capabilities to its single cell and spatial platforms.
- The company announced multi-year research collaborations with Cleveland Clinic and Lausanne University Hospital for diagnostic applications of single cell and spatial technologies for cancer care.
Concerns
- Reported revenue was $151.0 million, compared with $172.9 million for the corresponding period of 2025.
- License and royalty revenue was $1,942 (in thousands), compared with $27,751 (in thousands) in the corresponding prior-year period.
- Operating expenses increased 39% to $132.1 million, principally reflecting a $3.4 million gain on settlement in 2026 versus a $40.7 million gain on settlement in 2025.
- The company reported an operating loss of $19.6 million and net loss of $17.9 million, compared with operating income of $30.1 million and net income of $34.5 million in the corresponding prior-year period.
- China revenue was $14,968 (in thousands), compared with $23,170 (in thousands) in the corresponding prior-year period.
What to watch
- Execution against full-year 2026 revenue guidance of $610 million to $630 million.
- The customer response and early order flow for Atera.
- Revenue growth excluding non-recurring license and royalty revenue related to patent litigation settlements.
- The durability of gross margin following lower manufacturing costs, $2.6 million of tariff refunds, and lower inventory write-downs.
- Progress integrating Proteintech Genomics into the company’s multiomics strategy.
- Performance in China, where quarterly revenue was $14,968 (in thousands).
Balance sheet and cash flow
- Cash and cash equivalents and marketable securities were $552.0 million as of June 30, 2026.
- Cash and cash equivalents were $502,512 (in thousands) as of June 30, 2026, compared with $473,966 (in thousands) as of December 31, 2025.
- Marketable securities were $49,521 (in thousands) as of June 30, 2026, compared with $49,443 (in thousands) as of December 31, 2025.
Analysis
Second-quarter reported revenue was $151.0 million, compared with $172.9 million in the corresponding period of 2025. The reported decline reflects a substantial reduction in non-recurring license and royalty revenue related to patent litigation settlements. Excluding settlement revenue in both periods, revenue was $149.4 million and increased 3%. Products and services revenue was $149,094 (in thousands), compared with $145,157 (in thousands), while license and royalty revenue was $1,942 (in thousands), compared with $27,751 (in thousands).
Management, verbatim
The story of the quarter was the extraordinary customer response to Atera. We are highly encouraged by the engagement across the research ecosystem and the very strong early order flow.
Serge Saxonov, Co-founder and CEO of 10x Genomics
Combined with the continued momentum across the rest of the business and our strong operating foundation, we are uniquely well-positioned for the opportunities ahead.
Serge Saxonov, Co-founder and CEO of 10x Genomics
Not in the filing
stated, not guessed- Prior-quarter comparisons for reported metrics
- Non-GAAP operating income, net income, EPS, gross margin, or cash flow measures
- Operating cash flow
- Free cash flow
- Share repurchases
- Dividends
- Debt balances
- Full balance-sheet liabilities and stockholders’ equity information, as the provided filing text is truncated
- Guidance for gross margin, operating expenses, tax rate, EPS, operating cash flow, or free cash flow
- Prior outlook section supplied separately for formal actual-versus-prior-guidance comparisons
- Percentage changes for individual product-source and geographic revenue categories
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC 8-K (Item 2.02) with the company’s Q2 2026 financial results and updated full-year 2026 revenue guidance, plus business updates (acquisition and research collaborations).
Ticker impact
10x Genomics reported Q2 2026 results and raised full-year 2026 revenue guidance to $610M-$630M from $600M-$625M.
Bias toward upside on the guidance raise, with follow-through dependent on whether investors focus on revenue growth vs the operating loss and settlement-driven comparables.
The filing discloses a specific, time-sensitive guidance update and multiple operating metrics (gross margin, operating loss, cash). However, revenue is down year over year on a reported basis and operating loss widened, with several items explicitly tied to non-recurring settlement effects, which can temper the reaction.
Market effects
Signals demand resilience in single-cell and spatial workflows (Atera order flow) and continued investment in diagnostics collaborations, which can influence sentiment across life-science tools and multiomics peers.
Limited direct regional spillover; primarily affects US-listed biotech/life-science instrumentation sentiment.
Moderate global relevance via multi-year collaborations (Cleveland Clinic, Lausanne University Hospital) and acquisition strengthening multiomics capabilities.
Counterpoint
Investors may discount the guidance raise if they view it as normalization after settlement-related revenue and expense swings, given reported revenue and operating income both deteriorated year over year.
Key entities
- public_company10x Genomics, Inc.
Nasdaq-listed life science technology company; reported Q2 2026 results and raised FY 2026 revenue guidance.
- product_or_platformAtera
Company cited “extraordinary customer response” and “very strong early order flow” during the quarter.
- acquisition_targetProteintech Genomics (division within Proteintech Group)
10x Genomics acquired Proteintech Genomics to add advanced protein detection capabilities to its multiomics strategy.
- research_partnerCleveland Clinic
Announced multi-year research collaboration to advance diagnostic applications of single cell and spatial technologies for cancer care.
- research_partnerLausanne University Hospital
Announced multi-year research collaboration to advance diagnostic applications of single cell and spatial technologies for cancer care.
